Teva, AZ Conclude Patent Battle Over Byetta

Teva Pharmaceuticals and AstraZeneca have settled patent litigation with a licensing agreement that enables Teva to market and manufacture a generic version of AstraZeneca’s diabetes drug Byetta.

Under the deal, Teva would be allowed to market a generic for the drug in the U.S. starting in October 2017 or earlier, according to a Teva statement. All other terms of the deal were not disclosed.

AstraZeneca and its subsidiary, Amylin Pharmaceuticals, sued Teva in 2014 in U.S. District Court for the District of Delaware, accusing the company of violating seven patents for Byetta.